CYFRA 21.1 in patients with cervical cancer: Comparison with SCC and CEA

Anticancer Research

Volumn 25, Issue 3 A, 2005, Pages 1765-1771

  Molina, Rafael ^a   Filella, Xavier ^a   Augé, Jose M ^a   Bosch, Elvira ^a   Torne, Aureli ^a   Pahisa, Jaume ^a   Lejarcegui, Jose A ^a   Rovirosa, Angels ^a   Mellado, Begoña ^a   Ordi, Jaume ^a   Biete, Albert ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

CEA; Cervical cancer; Prognosis; SCC; Tumor markers

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CYTOKERATIN; CYTOKERATIN 19 FRAGMENT; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADJUVANT CHEMOTHERAPY; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA;

ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; KERATINS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SERPINS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 21244495257     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Boring CC, Squires TS, Tong T and Montgomery S: Cancer statistics 1994. CA Cancer J Clin 4: 7-26, 1994.
2. Duk JM, De Bruijn H, Groenier KH, Hollema H, ten Hoor KA, Krans M et al: Cancer of the uterine cervix: sensitivity and specificity of serum squamous cell carcinoma antigen determinations. Gynecol Oncol 39: 186-194, 1990.
3. Borras G, Molina R, Xercavins J, Ballesta A and Iglesias X: Squamous cell carcinoma antigen in cervical cancer. Eur J Gynaecol Oncol 13: 414-418, 1992.
4. Kato H, Morioka H, Tsutsui H, Aramaki S and Torigoe T: Value of tumor antigen (TA-4) of squamous cell carcinoma in predicting the extent of cervical cancer. Cancer 50: 1294-1296, 1982.
5. Leminen A, Alftan H, Stenman UH and Lehtovirta P: Chemotherapy as initial treatment for cervical carcinoma: clinical and tumor marker response. Acta Obstet Gynecol Scand 71: 293-297, 1992.
6. Ngan HY, Cheng GT, Yeung WS, Wong LC and Ma HK: The prognostic value of TPA and SCC in squamous cell carcinoma of the cervix. Gynecol Oncol 52: 63-68, 1994.
7. Ngan HYS, Chan SYM, Wong LC, Choy DTK and Ma HK: Serum squamous cell carcinoma antigen assays in the monitoring of radiotherapy response in carcinoma of the cervix. Gynecol Oncol 37: 260-263, 1990.
8. Rose PG, Baker S, Fournier L, Nelson BE and Huner RE: Serum squamous cell carcinoma antigen levels in invasive cervical cancer: prediction of response and recurrence. Am J Obstet Gynecol 10: 942-946, 1993.
9. Avåll-Lundqvist EH, Sjovall K, Nilsson BR and Eneroth PH: Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma. Eur J Cancer 28A: 1695-1702, 1992.
10. Chou CY, Wang ST, Kuo HC, Tzeng CC and Yao BL: Serum level of squamous cell carcinoma antigen and tumor size are useful to identify preoperatively patients at high risk of cervical cancer. Cancer 74: 2497-2501, 1994.
11. De Bruijn HW, Duk JM, van der Zee AG, Pras E, Willemse PH, Boonstra H et al: The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix. Tumor Biol 19: 505-516, 1998.
12. Scambia G, Benedette Panici P, Foti E, Amoroso M, Salerno G et al: Squamous cell carcinoma antigen: significance and role in the monitoring of neo-adjuvant chemotherapy response in cervical cancer. J Clin Oncol 12: 2309-2316, 1994.
13. Kornafel J and Wawrzkiewicz M: Evaluation of diagnostic usefulness of CEA, hGC and SCC antigens in cervical cancer patients. Eur J Gynaecol Oncol 39: 358-363 1989.
14. Molina R, Filella X, Lejarcegui JA, Pahisa J, Torné A, Rovirosa A et al: Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. Tumor Biol 24: 109-164, 2003.
15. Gaarenstroom KN, Bonfrer JMG, Kenter GG, Korse CM, Hart AAM et al: Clinical value of pre-treatment serum CYFRA 21-1, tissue polypeptide antigen and squamous cell carcinoma antigen levels in patients with cervical cancer. Cancer 76: 807-813, 1995.
16. Duk MJ, Aalders JG, Fleuren GJ, Krans M and de Bruijn HWA: Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix. Obstet Gynec 73: 661-667, 1989.
17. Borras G, Molina R, Xercavins J, Ballesta AM and Iglesias J: Tumor antigens CA 19.9, CA 125 and CEA in carcinoma of the uterine cervix. Gynecol Oncol 57: 205-211, 1995.
18. Dodd JK, Henry RJW, Tyler JPP and Houghton CRS: Cervical carcinoma: a comparison of four potential biochemical tumor markers. Gynecol Oncol 32: 248-252, 1989.
19. Duk JM, de Bruijn H, Klaas KH, Fleuren GJ and Aalders JG: Adenocarcinoma of the uterine cervix: prognostic significance of pre-treatment serum CA125, squamous cell carcinoma antigen and carcinoembryonic antigen levels in relation to clinical and histopathologic tumor characteristics. Cancer 65: 1830-1837, 1990.
20. Molina R, Filella X, Auge JM, Rifa J, Moreno V, Canals E et al: Tumour markers (CEA, CA125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as aid in histological diagnosis and prognosis: comparison with the main clinical and pathological prognostic factors. Tumor Biol 24: 209-218, 2003.
21. Molina R, Agusti C, Filella X, Jo J, Joseph J, Giménez N and Ballesta AM: Study of a new tumor marker, CYFRA 21-1 in malignant and nonmalignant diseases. Tumor Biol 15: 318-321, 1994.
22. Ferdeghini M, Gadducci A, Annicchiarico C, Prontera C, Melagnino G, Castellani C et al: Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix. Anticancer Res 13: 1841-1844, 1993.
23. Pras E, Willemse PH, Canrinus AA, de Bruijn HWA, Sluiter WJ, ten Hoor KA et al: Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment. Int J Rad Oncol Biol Phys 52: 23-32, 2002.
24. Yazigi R, Castillo R, Aliste G, Garrido J, Opazo A, Prado S et al: CYFRA 21-1 marker in carcinoma of the cervix. Int J Gynecol Cancer 10: 203-206, 2000.
25. Creaseman WT: New gynecologic cancer staging. Gynecol Oncol 38: 157-158, 1995.
26. Suzuki Y, Nakano T, Ohno T, Abe A, Morita S and Tsujii H: Serum CYFRA 21-1 in cervical cancer patients treated with radiation therapy. J Cancer Res Clin Oncol 126: 332-336, 2000.
27. Duk JM, Klaas H, de Bruijn H, Hollema H, ten Hoor KA, van der Zee A et al: Pre-treatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early stage cervical cancer. J Clin Oncol 14: 111-118, 1996.